Portage Biotech, IOx and Immunova
Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd
Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, is pleased to announce that it has entered into a Letter of Intent (“LOI”) with Immunova,
Portage Biotech Shares Double on Letter of Intent to Sell Subsidiary
Shares of Portage Biotech more than doubled after the company said it has entered into a letter of intent to sell one of its subsidiaries to Immunova. The stock was changing hands at $7.33 in early trading. Shares closed the market at $3.25 on Monday. The volatile stock is still down 80% since the start of the year.
Hosted on MSN3d
Portage Biotech Stock More Than Doubles On Immunova Deal Potential: Retail Sees Big OpportunityShares of Portage Biotech Inc. surged more than 150% on Tuesday morning, reaching levels last seen in late September. The ...
After spending most of the year hunting for options to stay afloat, cash-strapped Portage Biotech appears to have found ...
Portage Biotech stock is trading higher after the company announced it signed a letter of intent with Immunova for the ...
Portage Biotech, a clinical-stage immuno-oncology company, focuses on the development of innovative therapies that aim to transform the immune system’s ability to fight cancer. Their pipeline is ...
US equity futures were down ahead of Tuesday's opening bell as the Federal Reserve kicks off its policy-setting meeting. Dow Jones Industrial Average futures were down 0.5%, S&P 500 futures slipped 0.
Portage Biotech, Inc. ("Portage" or the "Company") (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback